Læknablaðið - 15.11.2003, Blaðsíða 32

FRÆÐIGREINAR / GIGTARLYF
14. Cheatum DE, Arvanitakis C, Gumpel M, Stead H, Geis GS.
An endoscopic study of gastroduodenal lesions induced by
nonsteroidal anti-inflammatory drugs. Clin Ther 1999; 21:992-
1003.
15. Blower AL, Brooks A, Fenn GC, Hill A, Pearce MY, Morant
S, et al. Emergency admissions for upper gastrointestinal dis-
ease and their relation to NSAID use. Aliment Pharmacol
Ther 1997;11:283-91.
16. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas
R, Schnitzer TJ, et al. Serious lower gastrointestinal clinical
events with nonselective NSAID or coxfb use. Gastroentero-
logy 2003; 124: 288-92.
17. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxici-
ty of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;
340:1888-99.
18. Gunnarsson í, Þjóðleifsson B, Oddsdóttir M, Magnússon J.
Blæðingar í efri hluta meltingarvegar: Uppgjör á Landspítala
1994. Læknablaðið 1997; 83:226-7.
19. Bjarnason I HJ, MacPherson AJ, Russell AS. Side effects of
nonsteroidal anti-inflammatory drugs on the small and large
intestine in humans. Gastroenterology 1993; 104:1832-47.
20. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-
inflammatory drugs affect blood pressure? A meta-analysis.
Ann Intern Med 1994; 121: 289-300.
21. Morgan TO, Anderson A, Bertram D. Effect of indomethacin
on blood pressure in elderly people with essential hyper-
tension well controlled on amlodipine or enalapril. Am J
Hypertens 2000; 13:1161-7.
22. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the
effects of nonsteroidal anti-inflammatory drugs on blood
pressure. Arch Intem Med 1993; 153: 477-84.
23. Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F,
Andrade P, et al. Influence of non-steroidal anti-inflammatory
drugs on renal function and 24h ambulatory blood pressure-
reducing effects of enalapril and nifedipine gastrointestinal
therapeutic system in hypertensive patients. J Hypertens 1995;
1: 925-31.
24. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL,
Quan H, et al. Adverse upper gastrointestinal effects of
rófecoxíb compared with NSAIDs. JAMA 1999; 282:1929-33.
25. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas
R, Davis B, et al. Comparison of upper gastrointestinal toxici-
ty of rófecoxib and naproxen in patients with rheumatoid art-
hritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
26. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T,
Whelton A, et al. Gastrointestinal toxicity with celecoxfb vs
nonsteroidal anti-inflammatory drugs for osteoarthritis and
rheumatoid arthritis: the CLASS study: A randomized con-
trolled trial. Celecoxíb Long-term Arthritis Safety Study.
JAMA 2000; 284:1247-55.
27. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D,
Brett C, et al. Stratifying the risk of NSAID-related upper
gastrointestinal clinical events: results of a double-blind out-
comes study in patients with rheumatoid arthritis. Gastro-
enterology 2002; 123:1006-12.
28. Juni P RA, Dieppe PA. Are selective COX 2 inhibitors
superior to traditional non steroidal anti-inflammatory drugs?
Adequate analysis of the CLASS trial indicates that this may
not be the case. BMJ 2002; 324:1287-8.
29. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE,
Verburg KM. Cyclooxygenase-2-specific inhibitors and
cardiorenal function: a randomized, controlled trial of cele-
coxíb and rófecoxíb in older hypertensive osteoarthritis
patients. Am J Ther 2001; 8: 85-95.
30. Hernandez-Diaz S, Rodriguez LA. Association between non-
steroidal anti-inflammatory drugs and upper gastrointestinal
tract bleeding/perforation: an overview of epidemiologic
studies published in the 1990s. Arch Intern Med 2000; 160:
2093-9.
31. Wolfe MM. Risk factors associated with the development of
gastroduodenal ulcers due to the use of NSAIDs. Int J Clin
Pract 2003; 135: 32-7.
32. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with
long term use of aspirin: meta-analysis. BMJ 2000; 321:1183-7.
33. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular
events associated with selective COX-2 inhibitors. JAMA
2001; 286: 954-9.
34. Arber N. Do NSAIDs prevent colorectal cancer? Can J
Gastroenterol 2000; 14: 299-307.
35. Thun MJ, Namboodiri MM, Heath CW, Jr. Aspirin use and
reduced risk of fatal colon cancer. N Engl J Med 1991; 325:
1593-6.
36. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Asch-
erio A, Willett WC. Aspirin use and the risk for colorectal
cancer and adenoma in male health professionals. Ann Intern
Med 1994; 121:241-6.
37. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of non-
steroidal anti-inflammatory drugs and incidence of colorectal
cancer: a population-based study. Arch Intern Med 1999; 159:
161-6.
38. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresa-
lier R, et al. A randomized trial of aspirin to prevent colorectal
adenomas. N Engl J Med 2003; 348: 891-9.
39. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Ker-
esztes R, et al. A randomized trial of aspirin to prevent colo-
rectal adenomas in patients with previous colorectal cancer. N
Engl J Med 2003; 348: 883-90.
40. Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim
L. Colorectal cancer prevention by non-steroidal anti-inflam-
matory drugs: effects of dosage and timing. Br J Cancer 1999;
81: 62-8.
41. Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of
colorectal cancer among long-term users of aspirin and non-
aspirin nonsteroidal antiinflammatory drugs. Epidemiol 2001;
12: 88-93.
42. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E,
Gordon GB, et al. The effect of celecoxíb, a cyclooxygenase-2
inhibitor, in familial adenomatous polyposis. N Engl J Med
2000; 342:1946-52.
43. Imperiale T. Aspirin and the Prevention of Colorectal Cancer.
N Engl J Med 2003; 348.
44. Bensen WG, Fiechtner JJ, McMiIlen JI, Zhao WW, Yu SS,
Woods EM, et al. Treatment of osteoarthritis with celecoxíb, a
cyclooxygenase-2 inhibitor: a randomized controlled trial.
Mayo Clin Proc 1999; 74:1095-105.
45. Frank McKenna AW, Justus J. Fiechtner, Alfonso E. Bello,
John G. Fort. COX-2 Specific Inhibitors in the Management
of Osteoarthritis of the Knee: A Placebo-Controlled, Rando-
mized, Double-Blind Study. J Clin Rheumatol 2001; 7:151-9.
46. Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde
D, Olivieri I, et al. Efficacy of celecoxíb, a cyclooxygenase 2-
specific inhibitor, in the treatment of ankylosing spondylitis: a
six-week controlled study with comparison against placebo
and against a conventional nonsteroidal antiinflammatory
drug. Arthritis Rheum 2001; 44:180-5.
47. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith
JB, Geis GS. Celecoxíb versus diclofenac in the management of
osteoarthritis of the knee. Scand J Rheumatol 2001; 30:11-8.
48. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun
A, Swannell AJ, et al. Omeprazole compared with misoprostol
for ulcers associated with nonsteroidal antiinflammatory
drugs. Omeprazole versus Misoprostol for NSAID-induced
Ulcer Management (OMNIUM) Study Group. N Engl J Med
1998; 338: 727-34.
49. Chan FK SJ. Role of acid suppressants in prophylaxis of
NSAID damage. Best Pract Res Clin Gastroenterol 2001; 15:
433-45.
50. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et
al. Celecoxíb versus diclofenac and omeprazole in reducing
the risk of recurrent ulcer bleeding in patients with arthritis. N
Engl J Med 2002; 347: 2104-10.
51. Þjóðleifsson B, Cockburn I. Review article: rabeprazole's
tolerability profile in clinical trials. Aliment Pharmacol Ther
1999; 13 (Suppl 5): 17-23.
52. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR,
Hwang C, et al. Efficacy and safety of esomeprazole compared
with omeprazole in GERD patients with erosive esophagitis: a
randomized controlled trial. Am J Gastroenterol 2001; 96:
656-65.
53. Yeomans ND, Jones R, Scheiman JM, Langstrom G , Lamm
M, et al. Esomeprazole provides effective control of NSAID-
associated upper GI symptoms in patients continuing to take
NSAIDs. American Gastroenterology Association meeting.
Orlando May 2003: Abstract 796.
54. Hawkey CJ, Jones R, Scheiman JM, Langstrom G , Lamm M,
et al. Esomeprazole improves quality of Iife in patients with
upper GI symptoms associated with long term NSAID
therapy. American Gastroenterology Association meeting.
Orlando May 2003: Abstract 795.
55. Lichtenberg FR. Are the benefits of newer drugs worth their
cost? Evidence from the 1996 MEPS. Health Aff (Millwood)
2001; 25: 241-51.
56. Lichtenberg FR. New drugs and lower costs. Am J Health Syst
Pharm 2002; 59:1894-5; author reply 1895.
57. Lichtenberg FR. Do (more and better) drugs keep people out
of hospitals? Am Econ Rev 1996; 86: 384-8.
856 Læknablaðið 2003/89